

The evolution of Covid-19 in Italy during the Summer 2020: analysis and interpretation of an unpredicted rest period

Giuseppe De Natale^{1,2}, Lorenzo De Natale³, Claudia Troise^{1,2}, Renato Somma^{1,4}, Vito Marchitelli⁵, Antonio Coviello⁴, Karen G. Holmberg⁶

¹ INGV, Osservatorio Vesuviano, 80124 Naples, Italy

² CNR-INO, 80078 Pozzuoli (NA), Italy

³ Faculty of Medicine, Università degli Studi di Napoli "Federico II", 80131 Naples, Italy

⁴ CNR-IRISS, 80134 Naples, Italy

⁵ Department of Mobility, Public Works, Ecology, Env, Puglia Region Government, 70100 Bari, Italy

⁶ Gallatin School of Individualized Study, New York University, USA

Abstract

The coronavirus (COVID-19) pandemic was particularly invasive in Italy during the period of March to the end of April 2020 then displayed a significant decrease both in the number of infections and in the seriousness of illness throughout the summer of 2020. In this discussion, we measure the seriousness of the disease by the ratio of Intensive Care Units (ICU) spaces occupied by COVID-19 patients and the number of still Active Cases (AC) each month from April to August 2020. We also use the ratio between the number of Deaths (D) and the number of Active Cases. What clearly emerges, from rigorous statistical analysis, is a progressive decrease of both the ratios, indicating progressive mitigation of the disease. This is particularly evident when comparing March-April with July-August; during the summer period the two ratios have become roughly 18 times lower. We test such sharp decreases against possible bias in counting active cases, and we confirm their statistical significance. We then interpret such evidence in terms of the well-known seasonality of the human immune system and the virus-inactivating effect of stronger UV rays in the summer.

Introduction

COVID-19 had devastating effects in the months of March-May 2020 in Europe. The CFR (Case Fatality Ratio) in European countries (updated on May 26, 2020) reached peaks close to 19% in France, about 16% in Belgium, and around 14% in Italy, UK and Hungary (Oke and Henegan, 2020). De Natale et al. (2020) discuss the reasons for the high CFR in Italy and these results could potentially be applied to other European countries with very high CFR rates. The main cause, recently confirmed by widespread randomized serological tests in Italy, was in fact the large underestimation of the true number of infections during the peak of pandemic. Recent studies indicate that the true number of infected people in Italy was around 1.5 million people, i.e. about six times the tested confirmed cases (ISTAT, 2020). With such a correction, the Infection Fatality Rate (IFR), which represents the true lethality of this infection, drops to about 2.3. As occurred in Italy, it is likely that other European countries experienced a higher infection rate than was understood at the time. Another problem, experienced in the most severely impacted Italian region Lombardy was the near-collapse of the health infrastructure accompanied by crisis management errors during the infection peak (De Natale et al., 2020). Lombardy had the highest CFR in Italy, at close to 20%. Other countries with very high CFR likely had similar contexts. It is clearly evidenced that countries with a very strong health system, like Germany, are characterised by much lower CFR (Oke and Henegan, 2020).

Starting in May 2020, COVID-19 seemed to lose much of its severity. This was very clearly evidenced to medical staff with direct experience with patients in the main hospitals and raised lively debates in Italy that were reported (besides Italian media) also by International press agencies (Reuters, 2020). Such limited, clinical observations raised political-social discussions in Italy about

54 the need to continue strict containment measures. The evolution of the infection transfers and
55 consequent illnesses during the summer and after the relaxation of the lockdown and other
56 containment measures was far milder than expected by epidemiological forecasts (Vespignani et al.,
57 2020; Vollmer et al., 2020). In this paper, we statistically analyse data of ICU occupation and
58 deaths due to COVID-19 as related to the number of active cases from the end of March to August.
59 When rigorously tested, the ratios of ICU occupation to active cases and the ratios of deaths to
60 active cases show significant changes, thus indicating a change in the evolution of the illness from
61 spring to summer 2020. The likely implications of such changes are then interpreted and discussed,
62 taking into account the possible factors affecting the illness: weakening of the virus, counting bias,
63 and changes in the immune response. The results and interpretation are then discussed in light of a
64 possible forecast of what kind of evolution we could expect in the coming months (Autumn-Winter
65 2020-2021). Finally, we discuss the implications of these observations, made in Italy, for the more
66 general worldwide situation.

67 **Data analysis**

68 We study the global, clinical evolution of COVID-19 in Italy using the data of ICU occupation
69 numbers, deaths, and active cases in different periods. As De Natale et al. (2020) point out, ICU
70 numbers and deaths are rather robust data whereas recording of active cases can be strongly biased
71 by heterogeneous testing, loss of asymptomatic cases, etc. Recently, the first results of a massive
72 testing campaign to randomly check the percentage of people expressing antibodies to SARS-CoV-
73 2 were released (ISTAT report, 2020). Such tests confirm, as first hypothesized by De Natale et al.
74 (2020), that the number of infected people was about six times larger than indicated by official
75 tests, reaching about 1.5 million people (instead of about 250.000 officially tested positive). In the
76 following analyses, we first assume that such high underestimation of active cases has been almost
77 constant during the analysed period; then, we test our results with respect to the maximum bias
78 implied by such an underestimation. Data on active cases, ICU occupation numbers, and deaths in
79 Italy are from the Department of Italian Civil Protection Repository (2020). Here, we report the
80 time evolution of the ratio between the number of people in ICU and the total number of 'active'
81 cases (i.e., total less recovered and deaths, at that time), indicated by ICU/AC.

82 In order to make our estimates more robust, we choose to consider another important and robust
83 indicator: the number of deaths. We therefore also use the ratio between the number of deaths and
84 the number of active cases, indicated as D/AC. In order to get more accurate estimates, we also
85 considered the average time lag from COVID-19 confirmation (the actual data on active infection
86 we have) and the ICU admission as from COVID-19 confirmation to death. According to Wilson et
87 al. (2020), the average time lag between infection confirmation and ICU admission is 6 days
88 whereas the average time lag between infection confirmation and death is 13 days. For this reason,
89 we shift the median day in which we compute the active cases to 6 days before the median day of
90 the ICU number computation; we accordingly shift the median day to compute the number of
91 deaths to 7 days after the ICU median day (so that there are 13 days between the days of active
92 cases computation and the corresponding days of deaths computation). As April 3, 2020 was the
93 day of maximum ICU occupation in Italy for COVID-19 cases we used the third day of each month,
94 from April to August, as the median day to consider ICU occupation numbers. The median days for
95 considering active cases and deaths are chosen accordingly with the described shifts: so that for
96 active cases we take the 27th or 28th of the month before (depending if it has 30 or 31 days), and
97 for deaths we take the 10th of each month considered. In order to obtain more robust estimates of
98 the various data, we choose to average the data during 7 days around each median day (considering
99 also 3 days before and 3 days after the median day). We then computed the two quantities -
100 ICU/AC and D/AC - as the respective averages for each month. The results, for months from April
101 to August, are reported in Table1 and Figure1. The data in Figure 1 show the statistical
102 uncertainties at 95% (2 standard deviations) and indicate that both the ratios sharply decrease, with
103
104

105 decreasing values clearly separated, well above the statistical uncertainty. Another way to look at
106 such marked change is to consider the ratios of ICU/AC and D/AC computed for April to each one
107 of the following months.

108 The computed values of such ratios are reported in Table 2, and shown in Fig.2.

109 As is clear, both the ratios progressively and rapidly increase: from April to June, the relative ratio
110 $(ICU/CA)_{April}/(ICU/CA)_{June}$ increases of a factor 7.9, and the relative ratios $(D/CA)_{April}/(D/CA)_{June}$
111 of a factor 6.2; from April to August, the relative ratio $(ICU/CA)_{April}/(ICU/CA)_{August}$ increases of a
112 factor 17.6 and the relative ratio $(D/CA)_{April}/(D/CA)_{August}$ of a factor 16.7.

113 These increases are exceptionally marked. Assuming the problems of estimating the true number of
114 active cases are constant in time they unequivocally indicate that the illness became progressively
115 milder during the summer months. The next step, however, is to consider the maximum possible
116 bias due to heterogeneity in the counting procedures of infected people. As we said, we are now
117 able to consider the massive underestimation of infection rates that occurred in Italy in the first
118 months of the pandemic; this error indicates a factor of six more people infected than officially
119 tested positive (ISTAT report, 2020). Then, in order to compute the maximum bias such a
120 fluctuating underestimation could imply in our computations we assume that all of the
121 underestimation occurred in the months of March-April and that in the last summer months we
122 succeeded in testing all COVID-19 positive cases. Such an assumption divides the March-April
123 ratios (ICU/AC and D/AC) by a factor 6 to test the obtained values against the values computed for
124 August (with data from July-August).

125 We then performed a rigorous test of hypothesis to determine if the observed increase of the ratios
126 in August, with respect to the ratios in April though decreased of a factor 6, is significant. We
127 applied the well-known Student's test (Spiegel, 1992).

128 The Student's test starts by assuming the following formula for the t-variable (Spiegel, 1992):
129

130
$$t = \frac{(\bar{X}_1 - \bar{X}_2) - (\mu_1 - \mu_2)}{\sqrt{\frac{1}{n} (s_1^2 + s_2^2)}} \quad [1]$$

131
132 where: \bar{X}_1 and \bar{X}_2 are the average values of ICU/AC (or D/AC) for April and August respectively,
133 and s_1^2 and s_2^2 are the respective variances as computed from the samples. In the assumption of the
134 null hypothesis, μ_1 and μ_2 , the true average values of the two samples are equal, and the value of
135 the t-variable can be tested with respect to the Student's distribution. For our data, the values result
136 $t=5.00$ for the ratios ICU/AC, and $t=3.7$ for the ratios D/AC, which are both largely out of 99%
137 probability limit for the Student's distribution (respectively, out of 99.9% and of 99.5%). So, we
138 can state that the decrease of the ratios ICU/AC and D/AC, from April to August, is significant for
139 both the variables, even if the maximum bias due to infection counting procedures is assumed, with
140 less than 0.5% probability of being wrong.

141 142 **Discussion and Conclusions**

143
144 Interpreting the very clear evidence that the disease has become progressively less severe,
145 particularly in July-August, is not as simple as it would appear. The simplest explanation could be
146 that the virus itself, which is continuously mutating and adapting to the host (Geoghegan et al.,
147 2018), lost much of its lethality. With COVID-19, however, we should consider that the severity of
148 the disease is mostly determined by the response of the human immune system (Song et al., 2020).
149 The scientific literature currently provides no clear evidence for the virus becoming substantially
150 mutated and less aggressive. There is evidence for some mutations which actually made the disease
151 less severe (Barnaby et al., 2020; Benedetti et al., 2020); however, there is no indication that such
152 mutations currently have a large diffusion (or have increased compared to past months) in order to
153 significantly mitigate the disease. Hence, the hypothesis that the observed mitigation is due to the
154 large diffusion of a significant virus mutation lacks scientific basis. It is well known that infectious

155 diseases (Fishman, 2007) as well as auto-immune diseases are characterized by an evident
156 seasonality (Iikuni et al., 2007; Moltchanova et al., 2009). The main reason for this appears to be
157 the seasonal variation of the human immune system response, which has been assessed even in
158 terms of gene expression (Dopico et al., 2015). In particular, during the summer the immune system
159 response is more effective and less inflammatory. It is proven that during European winters the
160 human immune system has a marked pro-inflammatory character, with increased levels of soluble
161 Il-6 receptor and C reactive protein (Dopico et al., 2015). An inflammatory response by the immune
162 system, with cytokine storms, has been recognised as the main factor leading to lung and/or other
163 organs failure and death (e.g. Song et al., 2020).

164 Hence, besides widespread evidence that almost all the flu-like epidemics are strongly dampened
165 during the summer, there is a very fundamental reason because this is even more so in the case of
166 COVID-19: in the acute phase, COVID-19 behaves like an autoimmune syndrome and so is
167 particularly sensitive to the seasonality of the immune response (Dopico et al., 2015; Iikuni et al.,
168 2007). Other researchers previously noted some seasonal/climate effects (e.g. Scafetta, 2020;
169 Carleton and Meng, 2020). In addition, it has been proven the summer sunlight rapidly inactivates
170 Sars-Cov-2 (Ratnesar-Shumate et al., 2020).

171 It is important to highlight that other explanations, based on the possible bias due to inhomogeneous
172 counting and/or mean age of the infected people in the different periods, as often claimed also on
173 the basis of a relatively younger age inferred for recently recorded infections (ISS, 2020), do not
174 appear to be sufficient to explain the significant decrease of the ICU/AC and D/AC in the summer
175 months. In addition to our demonstration here relative to the possible bias of inhomogeneous
176 counting, there is compelling evidence (Davies et al., 2020) that susceptibility to the virus of
177 population older than 20 years is more than double with respect to younger population. Such
178 evidence makes obviously very unlikely to imagine that only very young people in Italy are being
179 infected, and such infection does not spread also into the older population. The most likely
180 explanation of the inferred lower mean age of recent infections is that, actually, due to the
181 predominance of rather asymptomatic cases, the testing is mostly operated to control young people
182 coming back from summer vacations. Then, a very strong decrease of the seriousness of the disease
183 in the summer months appears the only realistic explanation of data.

184 What we have described in the Italian case seems to also be able to explain the comparatively low
185 lethality of the virus in recent months observed even in countries experiencing a very large number
186 of infections. Countries like the USA, India, Brazil, and almost all the South American and North
187 African countries, in which epidemics are active, are experiencing much lower CFR (Case Fatality
188 Rates) compared to what European countries experienced in the spring of 2020 (Oke and Henegan,
189 2020). Among them, the rate (CFR=0.8) in Israel is extremely low. Except in few cases (like Israel,
190 for instance) it is not probable that all of these countries are recording the real number of infection
191 cases with much higher precision than the European countries.

192 The largely mitigated effect of COVID-19 epidemics in Italy, despite the acute situation in the
193 months of March-April (De Natale et al., 2020), strongly validates its management of the epidemics
194 and the Italian lockdown strategy. We should note, in fact, that just after the first reopening, in the
195 middle of May 2020, epidemiological studies predicted a very large increase of infections, severe
196 cases, and deaths (Vespignani et al., 2020; Vollmer et al., 2020). Instead, despite the complete re-
197 openings of June 3, 2020, such dire forecasts have been completely discounted, confirming the
198 appropriateness of the response and progression from complete lockdown to gradual and then
199 complete re-opening.

200 As we conclude here, the recent mitigation of the illness is mostly due to the seasonality of immune
201 response, which is more effective and less inflammatory in the summer, combined with the strongly
202 germicidal power of the summer sun's UV rays. It remains to be seen what the practical
203 implications are for future procedures in order to avoid new epidemic waves. Obviously, despite
204 several media (and some doctors with direct clinical experience) claims that the virus has lost
205 power, if the illness mitigation is only attributable to the summer season we should be very careful

206 to continue the ‘mild’ actions of containment (social distancing, face masks in close environments,
207 etc.) in order to avoid, in autumn and winter, the possible escalation of epidemics with renewed
208 need for partial or total lockdowns. It is also possible that, superimposed on the seasonal effects,
209 there is also a weakening of the virus due to natural mutations and adaptations to the host; however,
210 we have no clear evidence for this in scientific literature. An eventual weakening of the SARS-
211 CoV-2 virus may be evident in autumn 2020, when the concomitant seasonal effect will no longer
212 apply. Before then, it will be good practice to maintain all the precautions to contain the epidemics.
213

214
215
216

217 **References**

218

219 Young, B.E.; Fong, S.W.; Chan, Y.-H.; Mak, T.-M.; Ang, L.W.; Anderson, D.E.; Lee, C.Y.-P.; Amrun,
220 S.N.; Lee, B.; Goh, Y.S.; Su, Y.C.F.; E Wei, W.E.; Kalimuddin, S.; Chai, L.Y.A.; Pada, S.; Tan,
221 S.Y.; Sun, L.; Parthasarathy, P.; Chen, Y.Y.C.; Barkham, T.; Lin, R.T.P.; Maurer-Stroh, S.; Leo, Y-
222 S.; Wang, L.-F.; Renia, L.; Lee, V.J.; Smith, G.J.D.; Lye, D.C.; Ng, L.F.N.. Effects of a major
223 deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: an
224 observational cohort study. *The Lancet* **2020**. DOI: 10.1016/S0140-6736(20)31757-8.
225

226

226 Benedetti, F.; Snyder, G.; Giovanetti, M.; Angeletti, S.; Gallo, R.; Ciccozzi, M.; Zella, D.
227 Emerging of a SARS-CoV-2 viral strain with a deletion in nsp1. **2020** 10.21203/rs.3.rs-62592/v1
228 (preprint).
229

230

230 Carleton, T.; Meng, K.C. Causal empirical estimates suggest COVID-19 transmission rates are
231 highly seasonal, medRxiv, **2020** doi: <https://doi.org/10.1101/2020.03.26.20044420>
232

233

233 Davies, N.G.; Klepac, P.; Liu, Y.; Prem, K.; Jit, M.; CMMID COVID-19 working group, Eggo,
234 R., M. Age-dependent effects in the transmission and control of COVID-19 epidemics. *Nat Med*
235 **2020**, **26**, 1205–1211 <https://doi.org/10.1038/s41591-020-0962-9>
236

237

237 De Natale, G.; Ricciardi, V.; De Luca, G.; De Natale, D.; Di Meglio, G.; Ferragamo, A.;
238 Marchitelli, V.; Piccolo, A.; Scala, A.; Somma, R.; Spina, E.; Troise, C. The COVID-19 Infection
239 in Italy: A Statistical Study of an Abnormally Severe Disease. *J. Clin. Med.* **2020**, **9**, 1564.
240

241

241 Department of Italian Civil Protection Repository. Available
242 online: [http://www.protezionecivile.gov.it/attivita-rischi/rischio-](http://www.protezionecivile.gov.it/attivita-rischi/rischio-sanitario/emergenze/coronavirus)
243 [sanitario/emergenze/coronavirus](http://www.protezionecivile.gov.it/attivita-rischi/rischio-sanitario/emergenze/coronavirus) (accessed on 4 August 2020).
244

245

245 Dopico, X.C.; Evangelou, M.; Ferreira, R.C.; Guo, H.; Pekalski, M.L.; Smyth, D.J.; Cooper, N.;
246 Burren, O.S.; Fulford, A.J.; Hennig, B.J.; Prentice, A.M.; Ziegler, A.-G.; Bonifacio, E.; Wallace,
247 C.; Todd, J.A.. Widespread seasonal gene expression reveals annual differences in human
248 immunity and physiology. *Nat Commun* **2015**, **6**, 7000. <https://doi.org/10.1038/ncomms8000>.
249

250

250 Fisman, D. N. Seasonality of infectious diseases. *Annu. Rev. Public Health* **2007**, **28**, 127–143
251

252

252 Geoghegan, J.L.; Holmes, E.C. The phylogenomics of evolving virus virulence. *Nat Rev Genet*
253 **2018**, **19**, 756–769. <https://doi.org/10.1038/s41576-018-0055-5>
254

255

254 Iikuni, N.; Nakajima, A.; Inoue, E.; Tanaka, E.; Okamoto, H.; Hara, M.; Tomatsu, T.; Kamatani, N.;
255 Yamanaka, H. What's in season for rheumatoid arthritis patients? Seasonal fluctuations in disease
256 activity. *Rheumatology* **2007**, **46**, 846–848. doi: 10.1093/rheumatology/kel414

257
258 ISS Epidemia COVID-19 published August 18, **2020** pp.22 Available online:
259 [https://www.epicentro.iss.it/coronavirus/bollettino/Bollettino-sorveglianza-integrata-COVID-](https://www.epicentro.iss.it/coronavirus/bollettino/Bollettino-sorveglianza-integrata-COVID-19_18-agosto-2020.pdf)
260 [19_18-agosto-2020.pdf](https://www.epicentro.iss.it/coronavirus/bollettino/Bollettino-sorveglianza-integrata-COVID-19_18-agosto-2020.pdf) (In Italian, accessed on August 28, 2020)
261
262 ISTAT Report, Primi risultati sull'indagine di sieroprevalenza sul Sars-Cov-2. **2020**. Available
263 online:<https://www.istat.it/it/files/2020/08/ReportPrimiRisultatiIndagineSiero.pdf> (In Italian,
264 accessed on August 3, 2020)
265
266 Moltchanova, E. V.; Schreier, N.; Lammi, N.; Karvonen, M. Seasonal variation of diagnosis of
267 Type 1 diabetes mellitus in children worldwide. *Diabet. Med.* **2009**, *26*, 673–678 .
268
269 Oke, J.; Heneghan, C. Global COVID-19 Case Fatality Rates; Nuffield Department of Primary Care
270 Health Sciences: Oxford, UK, **2020**; Available online: [https://www.cebm.net/global-COVID-19-](https://www.cebm.net/global-COVID-19-case-fatality-rates/)
271 [case-fatality-rates/](https://www.cebm.net/global-COVID-19-case-fatality-rates/) (accessed on 25 August 2020).
272
273 Reuters. New coronavirus losing potency, top Italian doctor says, Thomson Reuters, World News
274 May 31, 2020 Available online:[https://www.reuters.com/article/us-health-coronavirus-italy-](https://www.reuters.com/article/us-health-coronavirus-italy-virus/new-coronavirus-losing-potency-top-italian-doctor-says-idUSKBN23700Q)
275 [virus/new-coronavirus-losing-potency-top-italian-doctor-says-idUSKBN23700Q](https://www.reuters.com/article/us-health-coronavirus-italy-virus/new-coronavirus-losing-potency-top-italian-doctor-says-idUSKBN23700Q) (accessed on
276 August 28, 2020).
277
278 Ratnesar-Shumate, S.; Williams, G.; Green, B.; Krause, M.; Holland, B.; Wood, S.; Bohannon, J.;
279 Boydston, J.; Freeburger, D.; Hooper, I.; Beck, K.; Yeager, J.; Altamura, L.A.; Biryukov, J.; Yolitz,
280 J.; Schuit, M.; Wahl, V.; Hevey, M.; Dabisch, P. Simulated Sunlight Rapidly Inactivates SARS-
281 CoV-2 on Surfaces, *The Journal of Infectious Diseases*, **2020**, *222*, 2, 15, 214–222,
282 <https://doi.org/10.1093/infdis/jiaa274>
283
284 Scafetta, N. Distribution of the SARS-CoV-2 Pandemic and Its Monthly Forecast Based on
285 Seasonal Climate Patterns. *Int. J. Environ. Res. Public Health*, **2020**, *17*, 3493.
286
287 Song, P.; Li, W.; Xie, J.; Hou, Y.; You, C. Cytokine storm induced by sars-cov-2. *Clin. Chim.*
288 *Acta* **2020**, *509*, 280–287.
289
290 Spiegel, M. R. *Theory and Problems of Probability and Statistics*, New York: McGraw-Hill, **1992**,
291 pp. 116-117
292
293 Vespignani et al., 2020. Available online: *Il Sole 24 Ore* Infodata:
294 [https://www.infodata.ilsole24ore.com/2020/05/24/covid-19-modeling-italy-quattro-scenari-](https://www.infodata.ilsole24ore.com/2020/05/24/covid-19-modeling-italy-quattro-scenari-prevedere-contagio/)
295 [prevedere-contagio/](https://www.infodata.ilsole24ore.com/2020/05/24/covid-19-modeling-italy-quattro-scenari-prevedere-contagio/) (accessed on June 1, 2020).
296
297 Vollmer, M.A.C et al. Report 20: Using mobility to estimate the transmission
298 intensity of COVID-19 in Italy: A subnational analysis with future scenarios Technical Report;
299 Imperial College COVID-19 Response Team: London, UK, **2020**. Available
300 online: <https://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/covid-19/report-20-italy/>
301 (accessed on August 28, 2020)
302
303
304 WHO (World Health Organization).Rolling Updates on Coronavirus Disease (COVID-19); WHO:
305 Geneva, Switzerland, **2020**. Available online: [https://www.who.int/emergencies/diseases/novel-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019?gclid=Cj0KCQjw-af6BRC5ARIsAALPIIXu7eg96lFx3xa-)
306 [coronavirus-2019?gclid=Cj0KCQjw-af6BRC5ARIsAALPIIXu7eg96lFx3xa-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019?gclid=Cj0KCQjw-af6BRC5ARIsAALPIIXu7eg96lFx3xa-)

307 [l_DLkvSmCgRFGfB9FKIE6J8oLurUuiX80JiS_5kaAqZGEALw_wcB](https://doi.org/10.1101/2020.08.29.20184127) (accessed on August 28,
308 2020)

309

310 Wilson, N.; Kvalsvig, A.; Barnard, L.; Baker, M.G. Case-Fatality Risk Estimates for COVID-19
311 Calculated by Using a Lag Time for Fatality. *Emerg. Infect. Dis.* **2020**, 26(6):1339-1441.
312 <https://dx.doi.org/10.3201/eid2606.200320>

313

314

315 TABLES

316

	Ratio ICU/AC	Ratio D/AC
April	0.0593 +/- 0.0068	0.0083 +/- 0.0012
May	0.0144 +/- 0.0008	0.0019 +/- 0.0008
June	0.0076 +/- 0.0016	0.0013 +/- 0.0002
July	0.0046 +/- 0.0004	0.0009 +/- 0.0001
August	0.00334 +/- 0.00006	0.0005 +/- 0.0002

317 **Table 1.** Ratios ICU/AC and D/AC. Indicated uncertainties are statistical errors computed at 95%
318 probability level (2σ).

319

320


321

	Relative Ratio ICU/AC	Relative Ratio D/AC
April/May	4.11 +/- 0.54	4.37 +/- 0.84
April/June	7.8 +/- 1.4	6.2 +/- 1.3
April/July	12.7 +/- 1.9	9.3 +/- 1.8
April/August	17.8 +/- 2.1	15.8 +/- 3.5


322 **Table 2.** Relative ratios ICU/AC and D/AC between April and following months. Indicated
323 uncertainties are statistical errors computed at 95% probability level (2σ).

324


325
326 **FIGURES**



327
328 **Fig.1a** Ratio between ICU occupation and active cases in each month, from April to August. Error
329 bars are as in table 1 (statistical errors at 95% probability level, i.e. two standard deviations).
330




331
332 **Fig.1b** Ratio between deaths and active cases in each month, from April to August. Error bars are
333 as in table 1 (statistical errors at 95% probability level, i.e. two standard deviations).
334



335
336
337
338

Fig.2a Relative ratios of ICU/AC in April, with respect to the following months May to August. Error bars are as in table 1 (statistical errors at 95% probability level, i.e. two standard deviations).



339
340
341

Fig.2b Relative ratios of D/AC in April, with respect to the following months May to August. Error bars are as in table 1 (statistical errors at 95% probability level, i.e. two standard deviations).